Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last4,481 to 4,500 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Transitional Tobacco Care Management (TTCM) vs eReferral to State Tobacco Quitline (QL): Self-reported Continuous Tobacco Abstinence Since Hospital Discharge | 120 of 706 91 of 703 | 4.1 points 0.3 to 7.8 | 1,409 | NCT03603496 Post-Discharge Smoking Cessation Strategies: Helping HAND 4 |
| Transitional Tobacco Care Management (TTCM) vs eReferral to State Tobacco Quitline (QL): Tobacco Abstinence, Biochemically Confirmed | 110 of 706 96 of 703 | 1.9 points -1.8 to 5.6 | 1,409 | NCT03603496 Post-Discharge Smoking Cessation Strategies: Helping HAND 4 |
| Transitional Tobacco Care Management (TTCM) vs eReferral to State Tobacco Quitline (QL): deaths from any cause | 19 of 706 24 of 703 | -0.7 points -2.6 to 1.1 | 1,409 | NCT03603496 Post-Discharge Smoking Cessation Strategies: Helping HAND 4 |
| CADe Device vs Colonoscopy (Standard of Care): Serrated Lesions Detection Rate (SLDR) | 219 of 713 156 of 694 | 8.2 points 3.6 to 12.8 | 1,407 | NCT05275556 Gastroenterology Artificial INtelligence System for Detecting Colorectal Polyps (The GAIN Study) |
| CADe Device vs Colonoscopy (Standard of Care): Adenoma Detection Rate Including Carcinoma (ADR*) | 307 of 713 271 of 694 | 4.0 points -1.1 to 9.1 | 1,407 | NCT05275556 Gastroenterology Artificial INtelligence System for Detecting Colorectal Polyps (The GAIN Study) |
| CADe Device vs Colonoscopy (Standard of Care): Advanced Adenoma Detection Rate (aADR) | 59 of 713 60 of 694 | -0.4 points -3.3 to 2.6 | 1,407 | NCT05275556 Gastroenterology Artificial INtelligence System for Detecting Colorectal Polyps (The GAIN Study) |
| CADe Device vs Colonoscopy (Standard of Care): Polyp Detection Rate (PDR) | 425 of 713 364 of 694 | 7.2 points 2.0 to 12.3 | 1,407 | NCT05275556 Gastroenterology Artificial INtelligence System for Detecting Colorectal Polyps (The GAIN Study) |
| CADe Device vs Colonoscopy (Standard of Care): Flat Adenoma Detection Rate (fADR) | 21 of 713 19 of 694 | 0.2 points -1.6 to 2.0 | 1,407 | NCT05275556 Gastroenterology Artificial INtelligence System for Detecting Colorectal Polyps (The GAIN Study) |
| CADe Device vs Colonoscopy (Standard of Care): Proximal Adenoma Detection Rate (pADR) | 236 of 713 198 of 694 | 4.6 points -0.3 to 9.4 | 1,407 | NCT05275556 Gastroenterology Artificial INtelligence System for Detecting Colorectal Polyps (The GAIN Study) |
| CADe Device vs Colonoscopy (Standard of Care): Small Adenoma Detection Rate (sADR) | 236 of 713 201 of 694 | 4.1 points -0.7 to 8.9 | 1,407 | NCT05275556 Gastroenterology Artificial INtelligence System for Detecting Colorectal Polyps (The GAIN Study) |
| Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy: serious adverse events | 269 of 701 312 of 702 | -6.1 points -11.2 to -0.9 | 1,403 | NCT01287741 A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA) |
| CB-5945 vs Placebo: serious adverse events | 40 of 703 36 of 700 | 0.5 points -1.9 to 3.0 | 1,403 | NCT01696643 Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation |
| Sotagliflozin 400 mg vs Placebo: deaths from any cause | 1 of 699 0 of 703 | 0.1 points -0.4 to 0.8 | 1,402 | NCT02531035 A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone |
| Sotagliflozin 400 mg vs Placebo: serious adverse events | 48 of 699 23 of 703 | 3.6 points 1.3 to 6.0 | 1,402 | NCT02531035 A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone |
| Pembrolizumab/Vibostolimab vs Pembrolizumab: deaths from any cause | 6 of 701 1 of 701 | 0.7 points -0.1 to 1.7 | 1,402 | NCT05665595 A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010) |
| Short Storage vs Standard Issue: Organ Dysfunction | 129 of 669 133 of 732 | 1.1 points -3.0 to 5.2 | 1,401 | NCT01977547 Age of Blood in Children in Pediatric Intensive Care Units |
| qHPV Vaccine in Base Study vs qHPV Vaccine in Extension Study: Number of Participants Reporting SAEs From Month 18 Through Month 37 | 0 of 923 3 of 477 | -0.6 points -1.8 to -0.0 | 1,400 | NCT00092547 A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018) |
| GeneSight Psychotropic Tested vs Treatment As Usual: serious adverse events | 3 of 681 2 of 717 | 0.2 points -0.6 to 1.0 | 1,398 | NCT02109939 Genomics Used to Improve DEpression Decisions |
| MiStent® vs XIENCE EES: All-cause Death | 25 of 703 18 of 695 | 1.0 points -0.9 to 2.9 | 1,398 | NCT02385279 Study Comparing the MiStent SES Versus the XIENCE EES Stent |
| MiStent® vs XIENCE EES: Myocardial Infarction | 17 of 703 15 of 695 | 0.3 points -1.4 to 1.9 | 1,398 | NCT02385279 Study Comparing the MiStent SES Versus the XIENCE EES Stent |
Code
curl "https://conductscience.org/api/comparisons/v1?page=225"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=225
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT03603496-c8143564",
"title": "Transitional Tobacco Care Management (TTCM) vs eReferral to State Tobacco Quitline (QL): Self-reported Continuous Tobacco Abstinence Since Hospital Discharge",
"summary": "120 of 706 against 91 of 703; risk difference 4.1 points, 95% interval 0.3 to 7.8; NCT03603496, Post-Discharge Smoking Cessation Strategies: Helping HAND 4",
"record": "/library/comparisons/NCT03603496-c8143564",
"nct_id": "NCT03603496",
"kind": "outcome",
"participants": 1409,
"risk_difference": {
"value": 0.04052643667970937,
"lower": 0.003223483985579513,
"upper": 0.07779994484278108
},
"group_1": "120 of 706",
"group_2": "91 of 703",
"difference": "4.1 points",
"interval": "0.3 to 7.8",
"trial_title": "Post-Discharge Smoking Cessation Strategies: Helping HAND 4"
},
{
"id": "NCT03603496-d648a4ac",
"title": "Transitional Tobacco Care Management (TTCM) vs eReferral to State Tobacco Quitline (QL): Tobacco Abstinence, Biochemically Confirmed",
"summary": "110 of 706 against 96 of 703; risk difference 1.9 points, 95% interval -1.8 to 5.6; NCT03603496, Post-Discharge Smoking Cessation Strategies: Helping HAND 4",
"record": "/library/comparisons/NCT03603496-d648a4ac",
"nct_id": "NCT03603496",
"kind": "outcome",
"participants": 1409,
"risk_difference": {
"value": 0.019249755197272705,
"lower": -0.017737063109584873,
"upper": 0.0562184271773521
},
"group_1": "110 of 706",
"group_2": "96 of 703",
"difference": "1.9 points",
"interval": "-1.8 to 5.6",
"trial_title": "Post-Discharge Smoking Cessation Strategies: Helping HAND 4"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=226",
"request_id": "tBEeWtTxfA9ZRb1r"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
The conductscience.com catalog
One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.
Open Targets
One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.
Open Targets
One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.
ClinicalTrials.gov
One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.
Cellosaurus
One cell line with the problems Cellosaurus records for it, its relatives, the cell banks that hold it, and the papers that used it.
PubMed and NLM's journal list
One journal with its papers in PubMed since 1959, year by year, its retracted papers, errata and expressions of concern, and how many of its papers have a copy in PMC.
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant